InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,459.10
(
1.11%
)
US TECH 100
18,514.00
(
1.00%
)
Dow Jones
40,589.34
(
1.64%
)
Brent Oil
79.75
(
0.00%
)
Bitcoin
68,130.05
(
0.48%
)

Replies to post #359 on Novocure Ltd (NVCR)

Replies to #359 on Novocure Ltd (NVCR)
icon url

dstock07734

07/27/23 1:30 PM

#360 RE: jondoeuk #359

You were a big advocate when I said months ago with unequivocal evidence that something smelt real fishy about NVCR and the management were all about to abandon the ship.

Are you still holding your hope up? There is no future for the company. The tailspin mode will continue.
icon url

dstock07734

07/27/23 1:42 PM

#362 RE: jondoeuk #359

jondoeuk,

FYI, I don't short stocks, not to mention a stock related to cancer treatment. The problem with NVCR is that the management misled investors in the meantime they sold a big chunk of their position. That's why they are facing lawsuit.
icon url

norisknorewards

07/27/23 2:28 PM

#365 RE: jondoeuk #359

its over, accept it
icon url

supersteve13

07/27/23 2:33 PM

#367 RE: jondoeuk #359

jondoe how much are you down on this? :)
icon url

jondoeuk

07/27/23 3:50 PM

#368 RE: jondoeuk #359

https://seekingalpha.com/article/4620446-novocure-limited-nvcr-q2-2023-earnings-call-transcript

The LUNAR results have been accepted to a high impact journal and are now awaiting publication. The regulatory team recently completed the submission for CE Mark. The next step is for them to finalise an FDA PMA submission later this year. If it is approved, will add something to revenue, but I don't see it as a game changer, even in this large market.